Tuesday, October 20, 2026
12:00 p.m. – 1:15 p.m. ET
Please note this virtual symposium starts at 12:00 p.m. Eastern, 11:00 a.m. Central, 10:00 a.m. Mountain and 9:00 a.m. Pacific.
PRESENTING FACULTY
 |
David N. Lieberman, MD, PhD Child Neurologist Boston Children’s Hospital Harvard Medical School Boston, Massachusetts |
 |
Faith Dorsey Ihekweazu, MD, MS Associate Professor of Pediatrics Pediatric Gastroenterology, Hepatology, and Nutrition Baylor College of Medicine Texas Children’s Hospital Houston, Texas |
PROGRAM OVERVIEW
This innovative Rett syndrome (RTT) educational initiative will provide education for healthcare providers involved in the diagnosis and management of RTT. The interactive virtual symposium will open with a caregiver story, followed by expert-led, case-based education on developmental surveillance, screening, timely diagnosis, current and emerging treatment strategies, and updated data from ongoing clinical studies. An interactive animation and clinical analysis will address the efficacy, safety, and management of GI adverse events associated with trofinetide. The activity will conclude with practical strategies for managing GI comorbidities and treatment-related adverse events, as well as a brief presentation from a national RTT patient advocacy organization. The overall goal of this comprehensive summit is to optimize patient- and caregiver-centered care and improve the lives of children and families affected by RTT.
TARGET AUDIENCE
This educational activity is designed to meet the educational needs of pediatric neurologists, neurologists, neurology nurses, NPs, and PAs involved in the diagnosis and treatment of RTT.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Integrate systematic surveillance and screening guidelines and updated diagnostic criteria to ensure timely and accurate diagnosis of RTT
- Select therapy and appropriate clinical trials based on outcomes most valued by patients and caregivers
- Utilize GI management strategies to mitigate GI comorbidities and treatment-related adverse events
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.25 ANCC contact hours.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
